- Home
- ENGS vs RLMD Comparison
ENGS vs RLMD Comparison
Compare ENGS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGS
- RLMD
- Stock Information
- Founded
- ENGS 1998
- RLMD 2004
- Country
- ENGS United Kingdom
- RLMD United States
- Employees
- ENGS N/A
- RLMD N/A
- Industry
- ENGS
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- ENGS
- RLMD Health Care
- Exchange
- ENGS NYSE
- RLMD Nasdaq
- Market Cap
- ENGS 23.8M
- RLMD 22.0M
- IPO Year
- ENGS 2025
- RLMD N/A
- Fundamental
- Price
- ENGS $1.78
- RLMD $0.60
- Analyst Decision
- ENGS
- RLMD Buy
- Analyst Count
- ENGS 0
- RLMD 3
- Target Price
- ENGS N/A
- RLMD $5.00
- AVG Volume (30 Days)
- ENGS 399.3K
- RLMD 435.2K
- Earning Date
- ENGS 01-01-0001
- RLMD 08-06-2025
- Dividend Yield
- ENGS N/A
- RLMD N/A
- EPS Growth
- ENGS N/A
- RLMD N/A
- EPS
- ENGS N/A
- RLMD N/A
- Revenue
- ENGS $11,089,930.00
- RLMD N/A
- Revenue This Year
- ENGS N/A
- RLMD N/A
- Revenue Next Year
- ENGS N/A
- RLMD N/A
- P/E Ratio
- ENGS N/A
- RLMD N/A
- Revenue Growth
- ENGS 6.58
- RLMD N/A
- 52 Week Low
- ENGS $1.36
- RLMD $0.24
- 52 Week High
- ENGS $10.24
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- ENGS N/A
- RLMD 46.61
- Support Level
- ENGS N/A
- RLMD $0.59
- Resistance Level
- ENGS N/A
- RLMD $0.67
- Average True Range (ATR)
- ENGS 0.00
- RLMD 0.07
- MACD
- ENGS 0.00
- RLMD -0.02
- Stochastic Oscillator
- ENGS 0.00
- RLMD 30.37
About ENGS ENERGYS GROUP LTD
Energys Group Ltd provides end-to-end customized solutions and services involving the retrofitting of existing infrastructure to reduce their CO2 emissions. The Company's customers include large national account end-users, including universities, schools, hospitals and electrical distributors in the United Kingdom.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.